TB-500: The Healing Peptide Under the Microscope
Last updated: October 2026
TB-500 is a synthetic fragment of thymosin beta-4 (a naturally occurring 43-amino acid peptide), studied in preclinical research for tissue repair, wound healing, and anti-inflammatory effects. No completed human clinical trials exist for this specific fragment; the human trials cited on this page all tested full thymosin beta-4 as eye drops for dry eye.
(TB-500 Fragment)
Full Thymosin Beta-4
Human Uses
Build your own printable peptide tracker
A personalized injection log, weekly dosing schedule and dated calendar: your compounds filled in, ready to print. Free to build and preview; $5/month to unlock printing.
On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee discussed TB-500 (evaluated for wound healing) for the 503A compounding list. Any committee vote is a non-binding recommendation — not FDA approval and not legal to compound yet, pending HHS action and formal rulemaking. Read the full vote breakdown →
Four Key Mechanisms of Action
Thymosin beta-4 is a multifunctional peptide that has been studied through several biological pathways in preclinical models.
Binds monomeric G-actin to regulate cytoskeletal dynamics. This promotes cell migration, a critical step in wound healing and tissue repair. Tβ4 is the primary actin-sequestering peptide in mammalian cells.
Tβ4 is also studied for anti-inflammatory effects. None of the studies cited on this page measured inflammatory pathways or cytokines, so no specific anti-inflammatory mechanism is claimed here.
Tβ4 promoted endothelial cell migration in the embryonic mouse heart (Bock-Marquette 2004). None of the studies cited on this page measured new blood vessel formation in damaged tissue, so no angiogenesis effect is claimed here.
Tβ4 formed a complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt (PKB). It promoted heart-muscle and endothelial cell migration in the embryonic heart and enhanced cardiomyocyte survival in culture; after coronary ligation in mice it increased ILK and Akt activity in the heart (Bock-Marquette 2004).
Key Findings from Animal Studies
The most-cited results from preclinical research. Important: these are all animal or in-vitro studies unless specifically noted.
All progress bars below represent animal study data. Results in mice and rats do not reliably predict human outcomes. These numbers show preclinical promise, not proven human efficacy.
The Human Evidence Gap
The preclinical literature sounds impressive. But when you look at what actually involved humans, the picture changes dramatically.
TB-500 Fragment
Phase II Dry-Eye Trial
Human Uses
TB-500 vs BPC-157
Two of the most popular research peptides for healing — different proposed mechanisms, often stacked together.
- Studied preclinically for tissue repair (no human trials)
- Contains Tβ4's actin-binding region; the cell-migration data cited here used full Tβ4, not the fragment
- Route not established by the studies cited here (full Tβ4 was given as eye drops in the dry-eye trial)
- Prohibited by WADA (S2)
- Partial sequence of a protein isolated from human gastric juice; studied in rat Achilles tendon explants and cultured tendon fibroblasts (outgrowth, cell survival, migration) (PMID 21030672)
- Studied in a rat model using subcutaneously implanted sponges, including on new vessels and granulation tissue formation (PMID 10672992)
- Not compared head-to-head with TB-500 in any study cited here
- Also no FDA approval for human use
The "stack" is popular but unproven. Many in the peptide research community combine TB-500 and BPC-157. The usual rationale offered is that their proposed mechanisms are complementary, but none of the studies cited here tests or compares them. The evidence: zero human randomized controlled trials on the combination. It's theory, not science — yet.
Side Effects & Safety
What animal studies show — and what the community reports anecdotally. These are very different categories of evidence.
- None of the animal studies cited here reported toxicology or tolerability data
- Full Tβ4 (not the fragment) improved cardiac function in a mouse MI model
- Not animal data: the RegeneRx Phase II dry-eye trial was a human trial of full Tβ4 eye drops, reported with no adverse events
- Head rush / lightheadedness after injection
- Initial lethargy and fatigue (first few days)
- Injection site irritation and redness
- Temporary flu-like symptoms reported by some
- These are self-reports, not controlled observations
The cancer question: Thymosin beta-4 is upregulated in some cancer tissues. This has raised theoretical concerns. None of the studies cited on this page examined cancer, tumor growth or metastasis, so they cannot answer whether Tβ4 contributes to abnormal growth. This remains an open question.
Additional Therapeutic Applications
Beyond dermal wound healing, thymosin beta-4 research has explored cardiovascular, neurological, and ophthalmic applications.
In mouse dermal wounds, Tβ4 accelerated healing and increased wound contracture and collagen deposition (Philp 2003). Claims that it also reduces scarring or adhesions are not supported by the studies cited on this page.
In a mouse heart-attack model, the Bock-Marquette 2004 study showed enhanced cardiomyocyte survival and improved cardiac function after coronary-artery ligation in mice, via the ILK/Akt survival pathway.
Preclinical studies have explored Tβ4 for traumatic brain injury (TBI) and spinal cord injury recovery. None of the studies cited on this page looked at neural tissue, so no neuroprotective effect is claimed here, and human data is absent.
RegeneRx's RGN-259, a topical ophthalmic formulation of Tβ4, has been tested in human dry eye trials. In the 72-patient Phase II trial cited here, neither primary endpoint differed significantly from placebo, while several secondary measures (discomfort during an environmental challenge, central and superior corneal staining) improved, with no adverse events.
Cancer Concern Context: Elevated Tβ4 levels have been observed in certain cancer tissues, raising safety questions. None of the studies cited on this page examined cancer risk, so this page cannot speak to it either way. Correlation is not causation, and this remains an open research question.
Regulatory Status
TB-500 is not approved for human use anywhere in the world. Here's the full regulatory picture.
Not approved for human use. Investigational only. RegeneRx held an IND for ophthalmic Tβ4 (RGN-259) but no drug has been approved.
Investigational OnlyProhibited by the World Anti-Doping Agency. Listed under S2 — Peptide Hormones, Growth Factors. Prohibited at all times, in and out of competition.
WADA ProhibitedBanned in multiple jurisdictions. Several racehorses have tested positive for TB-500, leading to disqualifications and trainer suspensions.
Banned SubstanceAvailable from peptide suppliers labeled "for research use only." Not intended for human consumption. Quality and purity vary by supplier.
Research Use OnlyStudy Citations
The primary research behind the data on this page. Click PMID links to read the full papers on PubMed.
Fragment vs Full Peptide
TB-500 vs Full Thymosin Beta-4: Does It Matter?
TB-500 is a synthetic fragment, specifically the active region (amino acids 17-23) of the full 43-amino-acid thymosin beta-4 protein. Most peptide guides underplay this distinction, and it's increasingly discussed among practitioners who work with both forms.
| Property | TB-500 (Fragment) | Full TB4 |
|---|---|---|
| Structure | Active region (aa 17-23) | Complete 43 amino acids |
| Actin Binding / Cell Migration | Proposed — limited fragment data | ✅ Included + additional domains |
| Angiogenesis | No data cited | Endothelial cell migration (embryonic mouse heart) |
| Inflammation Modulation | No data cited | No data cited |
| Tissue Remodeling | Limited evidence | Increased collagen deposition (mice) |
| Cardioprotection | Not demonstrated | Improved cardiac function post-MI (mice) |
| Clinical Trials | Preclinical only | Phase 3 (dry eye, RGN-259) |
| Availability | Widely available (research) | Less common, higher cost |
Clinical Evidence: Full Thymosin Beta-4
The most advanced clinical work has been done with full TB4, not the fragment:
- RGN-259 (RegeneRx's topical ophthalmic formulation of full TB4) has been tested in clinical trials for dry eye syndrome, including Phase 3 trials (ARISE-2, NCT02974907; ARISE-3, NCT03937882) whose lead sponsor ClinicalTrials.gov lists as ReGenTree, LLC. In the published 72-patient Phase II trial cited here, neither primary endpoint (ocular discomfort, inferior corneal staining) differed significantly from placebo; several secondary measures (central and superior corneal staining, discomfort during an environmental challenge) improved significantly.
- Cardiac protection: Full TB4 improved early cardiomyocyte survival and cardiac function after coronary ligation in mice (Bock-Marquette 2004). These cardioprotective effects have not been demonstrated with the TB-500 fragment.
- Neuroprotection: Full TB4 has been explored in traumatic brain injury and spinal cord injury models, but none of the studies cited on this page measured neurological outcomes.
- Dermal wound healing: Full TB4 accelerated wound repair in aged mice and increased wound contracture and collagen deposition in diabetic mice; a seven-amino-acid actin-binding fragment promoted comparable repair in aged mice (Philp 2003). Claims of reduced scarring or adhesions are not supported by this study.
The Practical Bottom Line
TB-500 is unproven. The fragment's direct evidence on this page is one animal result: dermal wound repair in aged mice. None of the cited studies tested it in humans or in soft-tissue injuries. Its main practical advantage is that it is more accessible.
Full TB4 is better characterized. Most of the studies cited on this page used the full peptide, not the fragment. Claims that full TB4 heals chronic or stubborn injuries better are anecdotal; no cited study tests that.
The tradeoff is availability and cost. Full TB4 is harder to source, more expensive, and less commonly carried by research suppliers. TB-500 is the form more commonly sold, but neither form has been shown to work for human injuries.
Self-Assessment
Who Researches TB-500?
This Research Is Commonly Explored By People Who...
- Are researching thymosin beta-4 fragments and their role in cell migration and tissue repair
- Have chronic soft tissue injuries and want to understand the preclinical evidence on healing acceleration
- Are interested in comparing TB-500 with BPC-157 for different types of tissue repair
- Want to understand the research on actin regulation and its role in wound healing
- Are exploring recovery-focused peptide research beyond conventional anti-inflammatories
This Research May Not Be Relevant If...
- You're looking for human clinical trial data; TB-500 research is primarily preclinical and animal-based
- You have active cancer or a history of malignancy — thymosin beta-4 has been studied in cell proliferation contexts
- You want a ready-made recovery protocol — none of the studies cited here tested TB-500 itself in people
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
Who Is This For?
Commonly Researched For...
- • Slow-healing soft tissue injuries (muscle strain, ligament sprain): no human data
- • Inflammation from overtraining or repetitive motion: no human data
- • Post-surgical tissue remodeling: no human data
- • None of these uses has been tested in human trials; the cardiac findings cited here come from full Tβ4 in mice, not TB-500
Not Ideal If You...
- • Are pregnant or breastfeeding — no human safety data
- • Have active cancer — thymosin beta-4 promotes cell migration, and no study cited here tested whether it affects cancer growth
- • Are looking for a muscle-building compound: TB-500 has been studied for tissue repair, not muscle growth
- • Want a proven treatment — no use of TB-500 has been shown to work in humans
⚕️ Always consult a healthcare provider before starting any peptide protocol.
Key Takeaways
An honest assessment of where TB-500 research stands. The "don't know" column is intentionally longer.
- Tβ4 promotes cell migration and wound healing in animal models
- Improved cardiomyocyte survival and cardiac function in a mouse MI model
- A seven-amino-acid fragment promoted wound repair in aged mice comparably to full Tβ4
- Full Tβ4 eye drops missed both primary endpoints in a 72-patient dry-eye trial but improved some secondary measures, with no adverse events
- It's the primary actin-sequestering peptide in mammalian cells
- Whether any of this translates to humans (almost zero human data)
- Optimal dosing for any condition in humans
- Long-term safety profile in humans
- Whether the TB-500 + BPC-157 stack actually works (zero RCTs)
- If Tβ4 has any role in cancer promotion or progression
- Whether Tβ4's proposed anti-inflammatory effects hold up (not measured in the studies cited here)
- Whether injection site results translate to systemic benefits
- Purity and quality consistency from research suppliers
- Interaction effects with other medications
- Whether animal dose-response curves apply to humans at all
Related Resources
Related Resources
Research Supplies
Tools and supplies relevant to this research area.
Affiliate links support HighPeptides at no extra cost. As an Amazon Associate, HighPeptides earns from qualifying purchases.
Research-Grade TB-500
Research-grade TB-500 (a synthetic thymosin beta-4 fragment) with COA. Studied for tissue repair and recovery.
Browse TB-500 at Swiss Chems →Affiliate links support HighPeptides at no extra cost.
This page is for educational and informational purposes only. It is not medical advice. TB-500 (a synthetic fragment of thymosin beta-4) is NOT approved by the FDA for human use. Suppliers sell it labeled "for research use only." The studies cited are overwhelmingly preclinical (animal and in-vitro). Always consult a qualified healthcare provider before making any decisions about your health. HighPeptides does not sell peptides. Supplier and product links on this page are affiliate links, and HighPeptides may earn a commission on purchases.
Research Supplier
TB-500 from Swiss Chems, a research peptide supplier.
Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.